<DOC>
	<DOCNO>NCT01610999</DOCNO>
	<brief_summary>In order keep immune system healthy lifetime , certain cell bone marrow lymph node call stromal cell nurture immune cell protect damage . Stromal cell blood cell communicate use protein call SDF1a . The investigator think cancer cell include lymphoma multiple myeloma trick stromal cell help avoid damage chemotherapy use SDF1a . Plerixafor drug develop block effect SDF1a approve Federal Drug Administration ( FDA ) use human help release blood stem cell bone marrow use transplantation . The use plerixafor interrupt communication stromal cell cancer approve FDA experimental .</brief_summary>
	<brief_title>Pilot Study Lymphoid Tumor Microenvironmental Dysruption Prior Autologous Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Age 18 year old Subjects must document , relapsed/refractory highrisk primary lymphoid malignancy Subjects must evidence residual disease prior transplant , need measurable strictly evaluable disease Subjects must eligible candidate high dose chemotherapy either BEAM singleagent melphalan preparative regimen autologous stem cell transplantation Tufts Medical Center ( See Appendix B anticipate transplant schedule ) Subjects must able provide inform consent research procedure Uncontrolled infection Active heart disease evidence myocardial infarction within 6 month , uncontrolled arrhythmia , angina . Creatinine clearance estimate &lt; 50 ml/min . HIV infection evidence active chronic hepatitis Unable unwilling comply require study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>